Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 22nd 2017

Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas

Laura Joszt, MA

Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.

November 21st 2017

Analysis Identifies Attributes That Likely Contribute to High-Value Oncology Care

Jaime Rosenberg

An analysis using mixed quantitative and qualitative methods, as well as site visits to 7 US oncology practices, identified 13 attributes within 5 themes that potentially contribute to high-quality care at a relatively low total cost.

November 18th 2017

Navigators Offer Touch Points on Patients' Cancer Journey

Mary Caffrey

The evolution of the navigator role has been an important development in cancer care, according to panelists who offered various perspectives on helping patients along the cancer journey.

November 18th 2017

NQF and CAPC Team Up to Set Quality Standards for Community-Based Serious Illness Care

Jaime Rosenberg

With the growing shift to community-based and patient-centered care, the National Quality Forum (NQF) and the Center to Advance Palliative Care (CAPC) have launched initiatives to ensure that patients with serious illness receive safe, effective, and high-quality care. At the same time, professionals in the healthcare industry are highlighting the importance of integrating this type of care into the oncology practice.

November 17th 2017

ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy

AJMC Staff

With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.

November 17th 2017

Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says

Mary Caffrey

High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.

November 17th 2017

Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices

Jaime Rosenberg

Authors of the study found that the mean total, chemotherapy, and physician costs were all lower in community settings compared with hospital-based settings for patients with breast, lung, and colorectal cancer. There were also fewer emergency department visits both 3 and 10 days following treatment.

November 17th 2017

FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts

Mary Caffrey

FDA on Thursday authorized a faster approval path for a next-generation sequencing assay developed at Memorial Sloan Kettering Cancer Center (MSK) that represents both a scientific and regulatory breakthrough at the agency.

November 16th 2017

Predicting Which Patients Will Benefit From Immunotherapy

AJMC Staff

A mathematical model may help providers better understand which patients will benefit from certain immunotherapy.

November 15th 2017

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

AJMC Staff

Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.

November 14th 2017

Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials

As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.

November 14th 2017

Do Oral Parity Laws Reduce OOP Spending for Patients?

Surabhi Dangi-Garimella, PhD

According to a new analysis by Stacy Dusetzina, PhD, and colleagues, state oral parity laws—devised to equate out-of-pocket (OOP) spending for patients, irrespective of whether their treatment is an oral agent or an infusion—are not consistent with reducing patient OOP costs for oral anticancer agents.

November 14th 2017

The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives

Brock O&rsquo Neil, MD Mark Tyson, MD Amy J. Graves, SM, MPH Daniel A. Barocas, MD, MPH Sam S. Chang, MD, MBA David F. Penson, MD, MPH Matthew J. Resnick, MD, MPH

We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.

November 12th 2017

NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments

Smita Jaggernauth, PharmD

A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.

November 11th 2017

Podcast: This Week in Managed Care—Healthcare on Election Day 2017, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

November 10th 2017

This Week in Managed Care: November 10, 2017

This week, the top managed care stories included a vote in Maine to expand Medicaid and other election day 2017 results; CMS issued final rules for the DIabetes Prevention Program; and a report from the American Society of Clinical Oncology highlighted the link between alcohol consumption and cancer.

November 8th 2017

Mutation May Be Associated With Resistance to NSCLC Immunotherapy

Smita Jaggernauth, PharmD

A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).

November 8th 2017

The American Journal of Managed Care® Announces Dr Michael Kolodziej as the Keynote Speaker for the Patient-Centered Oncology Care® Meeting

Leading healthcare innovation officer to share information about digital health, managed services, and provider sectors in the healthcare arena.

November 8th 2017

Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business

November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

AJMC Staff

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

November 8th 2017

ASCO: Alcohol Linked to Several Types of Cancer

Jaime Rosenberg

According to evidence gathered by the American Society of Clinical Oncology (ASCO), alcohol consumption is linked with an increased risk of cancer and can negatively impact cancer treatment.

November 7th 2017

Study to Explore Link Between Diabetes, Pancreatic Cancer

Mary Caffrey

Rising rates of diabetes and obesity have been cited in the fact that pancreatic cancer is expected to be the second-leading cause of cancer death by 2020.

November 7th 2017

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

Jaime Rosenberg

With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.

November 5th 2017

3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology

Alison Rodriguez

Recent advancements in technology, specifically in detection methods, have demonstrated significant improvement in how early patients are diagnosed with breast cancer and treated.

November 4th 2017

Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer

Laura Joszt, MA

In a pair of interviews, experts discuss neutropenia resulting from treatment of metastatic breast cancer with CDK4/6 inhibitors.

November 3rd 2017

This Week in Managed Care: November 3, 2017

AJMC Staff

This week, the top managed care news included the first day of open enrollment; data from CMS that indicate the progress accountable care organizations are making; and findings that most people with obesity aren't get screened for it or getting care.

November 3rd 2017

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer

Jaime Rosenberg

Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.

November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

November 1st 2017

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez

The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.

November 1st 2017

Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care

As cancer care becomes more expensive and complex, the role of the pharmacist is expanding, from managing the shift to greater use of oral therapies to navigating the revenue cycle, as explored in the new issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care.®

...

63 64 65 66 67 68 69 70 71

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions